{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:59:20Z","timestamp":1785473960779,"version":"3.56.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Achieving pathological complete response (pCR) after neoadjuvant treatment has become one of the most influential outcomes shaping organ preservation strategies, treatment intensification protocols, and long-term oncological decision-making in locally advanced rectal cancer (LARC). Current response assessment, however, remains dependent on delayed structural evaluations \u2014 magnetic resonance imaging (MRI), endoscopy, and postoperative pathology \u2014 that measure the consequences of tumor regression rather than the biological process generating it. We hypothesize that response to neoadjuvant treatment reflects the temporal dynamics of tumor immune microenvironment (TIME) remodeling: treatment-induced immune activation may precede measurable morphological change, generating immune trajectories that diverge toward complete elimination or toward resistance. We propose that serial, biology-anchored tumor sampling \u2014 rather than a single baseline biopsy \u2014 can capture these trajectories and support earlier, biologically informed prediction of pCR and sustained clinical complete response (cCR). This article presents the biological rationale for the hypothesis, defines a four-phase mechanistic model of immune remodeling, proposes a measurable and feasibility-conscious biomarker panel with a data-driven scoring approach, states five falsifiable predictions, and outlines a prospective validation framework \u2014 including its ethical prerequisites, procedural safety considerations, and analytic handling of treatment-regimen heterogeneity and tumor spatial heterogeneity.<\/jats:p>","DOI":"10.3389\/fonc.2026.1910961","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:24:44Z","timestamp":1785471884000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early prediction of pathological complete response in rectal cancer: a dynamic immune remodeling hypothesis during neoadjuvant treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Serdar","family":"Gumus","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Faculty of Medicine, \u00c7ukurova University","place":["Adana, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem Kaan","family":"Parsak","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Faculty of Medicine, \u00c7ukurova University","place":["Adana, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7176","article-title":"Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer","volume":"29","author":"Maas","year":"2011","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"An der Valk","year":"2018","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-12275-9","article-title":"MRI to guide clinical management of rectal cancer: updated consensus recommendations from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR): Part II\u2014restaging and response evaluation","volume":"36","year":"2026","journal-title":"Eur Radio"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01125-9","article-title":"The crying need for a better response assessment in rectal cancer","volume":"24","author":"Amintas","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.11.019","article-title":"Response assessment after (chemo)radiotherapy for rectal cancer: why are we missing complete responses with MRI and endoscopy","volume":"45","author":"van der Sande","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0337","article-title":"A diagnostic biopsy-adapted Immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy","volume":"26","author":"El Sissy","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-011-9273-4","article-title":"Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy","volume":"30","author":"Kepp","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040930","article-title":"Biomarkers of radiotherapy-induced immunogenic cell death","volume":"10","author":"Vaes","year":"2021","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1703449","article-title":"Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology","volume":"9","author":"Vanmeerbeek","year":"2020","journal-title":"OncoImmunology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101231","article-title":"Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and spatial transcriptomics","volume":"4","author":"Qin","year":"2023","journal-title":"Cell Rep Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69219","article-title":"Radiation and immunotherapy: a synergistic combination","volume":"123","author":"Kalbasi","year":"2013","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1054598","article-title":"The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.14744\/ejmi.2022.73745","article-title":"The predictive role of immunohistochemical FoxP3 and CD163 expression in response to neoadjuvant therapy of rectal carcinomas","volume":"6","author":"Ozdemir","year":"2022","journal-title":"Eurasian J Med Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.coi.2017.01.005","article-title":"Immunoprofiling as a predictor of patient's response to cancer therapy: promises and challenges","volume":"45","author":"Bethmann","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","article-title":"Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer","volume":"5","author":"Teng","year":"2015","journal-title":"Am J Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00043","article-title":"Prediction of treatment efficacy in locally advanced rectal cancer using a clinical and magnetic resonance imaging\u2013based radiomics-immunological model for total neoadjuvant therapy","volume":"2","author":"Hu","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Society: Ser B (Methodological)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-022-00725-1","article-title":"Distinct tumor microenvironment landscapes of rectal cancer for prognosis and prediction of immunotherapy response","volume":"45","author":"Bu","year":"2022","journal-title":"Cell Oncol (Dordrecht)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1556386","article-title":"Single-cell and spatial transcriptomic analysis reveals tumor cell heterogeneity and underlying molecular program in colorectal cancer","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:24:46Z","timestamp":1785471886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1910961"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1910961","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1910961"}}